Toripalimab (3 cycles in neoadjuvant and 1 cycle in adjuvant setting with PDC followed by toripalimab alone up to 13 cycles) was also administered to stage II-IIIB (N2 stage) NSCLC without EGFR or ALK mutations in NEOTORCH trial in China which also showed significant benefits with EFS at 2 years was 64.7% versus 38.7% with HR of 0.4 with median EFS not reached in toripalimab versus 15.1 months in the placebo arm with mPR of 48.5% versus 8.4% and pCR of 24.8% versus 1.0% [18]. This evidence concerns the gene ALK and non-small cell lung carcinoma.